ClinicalTrials.gg
RecruitingNCT05156879Updated Jan 24, 2022

Aspirin for the Management of Endometriosis-associated Pelvic Pain

A Phase 4 interventional study of Aspirin and Drospirenone ethinyl estradiol in Pelvic Pain, sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-01-24.

Sponsored by Women's Hospital School Of Medicine Zhejiang University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pelvic Pain with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Pelvic Pain · China.

Planned enrollment
5th of 12
220 · median 198
Started
2021
with 2 others
Phase 4
Only one
of the 14
Registered
7th of 14
by date
Lead sponsor
1 of 14
Women's Hospital School Of Medicine Zhejiang University

Among the 14 studies in Pelvic Pain with a site in China, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2021, is the only one in phase 4, and was the 7th registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

5 of the 14 studies in Pelvic Pain with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pelvic Pain with a site in China, or all of them as a file.
02

Study summary

Endometriosis-associated pelvic pain (EAPP) is common in endometriosis and pain control is an important goal of long-term management. Non-steroidal anti-inflammatory drugs and oral contraception are the two first line therapies for endometriosis. High quality study about aspirin for the EAPP is absent. In this study, the investigators hypothesis that aspirin is effective in controlling EAPP. A randomized, open, and controlled study will be implemented. "participants with EAPP with visual Analogue Scale(VAS)>30 mm will be included and low dose aspirin(75mg/day) be prescribed. Yasmin(Drospirenone ethinyl estradiol tablet) will be used as positive control. The primary efficacy end points is the reduction of the pain score of EAPP at 24th week assessed with VAS score. Pelvic examination, sonography and blood test will be to performed to evaluate the lesion and coagulation function. The adverse event and medication compliance will be investigated. The aim of this study is to explore the efficacy and safety of low dose aspirin therapy in management of EAPP. This study will provide new options for the long-term management of endometriosis, which will help reduce the medical cost of endometriosis.

Read the detailed description

Endometriosis-associated pelvic pain (EAPP) is common in endometriosis and pain control is an important goal of long-term management. Non-steroidal anti-inflammatory drugs and oral contraception are the two first line therapies for endometriosis.However, there is currently a lack of high-quality clinical studies of nonsteroidal anti-inflammatory analgesic in controlling EAPP. The aim of this study is to explore the efficacy and safety of low dose aspirin therapy in management of EAPP. In this study, the investigators hypothesis that aspirin is effective in controlling EAPP. A randomized, open, and controlled study will be implemented. Subjects were recruited in strict accordance the inclusion and exclusion criteria at the outpatient clinic. Patients with EAPP with visual Analogue Scale(VAS:0-100mm)>30mm will be included. Eligible subjects were randomized according to a computer-generated randomization schedule to to receive aspirin(75mg/day)or Yasmin(Drospirenone ethinyl estradiol tablet) in a ratio of 1:1. Specific doctors will be designated for the disease diagnosis and ultrasonic examination.The investigators were guided by EAPP pain score and drug use management. The primary efficacy end points is the reduction of the pain score of EAPP at 24th week assessed with VAS score. Pelvic examination, sonography and blood test will be to performed to evaluate the lesion and coagulation function. The specification of the CONSORT case report system will be implemented. Sample size assessment according equivalence study.Follow-up and loss cases were strictly controlled. A two-sided test will performed with beta=0.80 and αlpha=0.025. The expected loss rate is calculated at 15%. 220 cases will be enrolled with 110 cases in each group. The study will be accepted regular monitoring and inspection.

03

Conditions studied

  • Pelvic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dysmenorrhea or non-cyclical pelvic pain lasts for more than 3 months, and the VAS pain score is larger than 30mm
  • diagnosed as endometriosis
  • Willing to participate in clinical trials and sign

Exclusion criteria

Exclusion Criteria:

  • Those who have a clear surgical treatment plan due to various diseases within 6 months
  • Suspected or suffering from malignant tumor
  • less than 8g/dl
  • women with to the use of aspirin or oral
  • with other painful disease other than endometriosis
  • Active bleeding from other areas or undiagnosed abnormal vaginal bleeding
  • drug adminstration within 3 months including oral contraceptives, dienogest, Mirena or GnRH-a preparations, analgesics/Chinese medicines or proprietary Chinese medicines, etc.
  • Pregnancy status or breastfeeding
  • Any disease or symptom that may affect the implementation of the study or the interpretation of the results
  • Participate in other clinical trials at the same time
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Aspirin

    Aspirin Enteric-coated Tablets,75mg/day,24 weeks

    Drug: Aspirin

  • Active comparator
    Drospirenone ethinyl estradiol

    Drospirenone ethinyl estradiol,one tablet/day for 21 consecutive days, 28 days as a cycle of use,24 weeks

    Drug: Drospirenone ethinyl estradiol

Interventions

  • 75mg, one time/day

  • DrugDrospirenone ethinyl estradiol

    1 table/day, 21 consecutive days, 28 days as a cycle of use

06

What researchers measure

Primary outcomes

  1. visual Analogue Scale

    a scale with 0-100 mm values, higher scores mean a worse outcome

    Time frame: baseline , 12 weeks after treatment , and 24 weeks of treatment

Secondary outcomes

  1. Tenderness

    Tenderness during pelvic examination from 1 to 4,higher scores mean a worse outcome

    Time frame: baseline , 12 weeks of treatment , and 24 weeks of treatment

  2. size of endometrioid lesions

    endometrioid lesions detected by sonorgraphy

    Time frame: baseline , 12 weeks of treatment , and 24 weeks of treatment

  3. C reactive protein

    a biomarker of inflammation

    Time frame: baseline , 12 weeks of treatment , and 24 weeks of treatment

  4. carbohydrate antigen 125

    a biomarker of endometriosis

    Time frame: baseline , 12 weeks of treatment , and 24 weeks of treatment

  5. platelets counts

    associated with inflammation and wound healing

    Time frame: baseline , 12 weeks of treatment , and 24 weeks of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Dec 2024, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Dec 14, 2021
StartActual
Dec 23, 2021
Primary completionEst.
Dec 2024
CompletionEst.
Jun 2025
Last update
Jan 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05156879
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Responsible party
Sponsor
First posted
Dec 14, 2021
Start date
Dec 23, 2021
Primary completion
Dec 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
Jan 24, 2022

Study contacts

Zhengyun Chen, Master
Contact
5504004@zju.edu.cn
0086-13805727504
Zhengyun Chen, Master
principal investigator · Women's Hospital School Of Medicine Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion